DiagnaMed Enters into License Agreement with University of Miami for Brain Health Platform for Integration with CERVAI, a Brain Health AI Platform Leveraging Generative AI

DiagnaMed Holdings Corp. a digital health generative AI company, is pleased to announce that it has entered into a license agreement with the University of Miami (“UM”) for the development and commercialization of intellectual property of a novel brain health platform for the evaluation, diagnosis and monitoring of brain health, such as Alzheimer’s disease and related dementias (“ADRD”), which will be incorporated with CERVAI, the Company’s proprietary Brain Health Artificial Intelligence (“AI”) Platform leveraging Generative AI. The UM brain health platform was invented by James E. Galvin, M.D., M.P.H., Professor of Neurology and Psychiatry and Behavioral Sciences at the University of Miami Miller School of Medicine and the founding Director of the Comprehensive Center for Brain Health at the University of Miami Health System.

Read More Interview: AiThority Interview with Anthony Katsur, Chief Executive Officer at IAB Tech Lab

“We continue to strengthen the potential of CERVAI, our proprietary Brain Health AI Platform leveraging Generative AI, by integrating a clinically validated novel brain health solution from the University of Miami, which will allow us to evaluate overall brain health and provide actionable data to implement personalized interventions for cognitive decline for the millions of people suffering from mental health and neurodegenerative diseases,” said Fabio Chianelli, Chairman of DiagnaMed.

The UM brain health platform features various novel brain function assessments and tools to evaluate overall brain health, ADRD risk factors, cognitive performance, and evidence of risk of further decline and future impairment, which are validated against clinical gold standards of normal and impaired cognitive function. The UM brain health platform can intake the inputs of these assessments and output a patient risk score, from which tailored interventions, including medications and clinical trial enrollment, can be implemented in at-risk individuals to decrease the development or progression of cognitive decline.

With the integration of UM’s brain health platform, CERVAI™ will add the ability to delay or prevent the onset of cognitive decline, thereby improving the quality of life for patients and caregivers, providing a diagnostic application which can comprehensively and objectively produce a risk assessment to inform a tailored intervention and enhance enrollment in prevention studies and clinical trials of disease-modifying therapies.

AiThority Interview : AiThority Interview with João Graça, Co-founder and CTO at Unbabel

CERVAI is a brain health AI platform leveraging generative AI that aims to predict and monitor brain age and provide actionable insights and tools to diagnose, prevent or improve cognitive decline for mental health and neurodegenerative disorders. CERVAI™ consists of an electroencephalogram-based (“EEG”) headset and machine-learning technique and integrates proprietary software and web applications into a unified turnkey pipeline of standardized EEG and data recording protocols and unique brain health assessment tools generated rapidly by self-report or clinician-observed measures, each capturing different aspects of brain health to evaluate overall brain health, output a patient risk score, and provide actionable points generated by GPT-3 to develop precision medicine-like, personalized treatment plans and interventions for mental health and neurodegenerative conditions.

DiagnaMed Holdings Corp. (CSE: DMED) is focused on the development and commercialization of CERVAI™, a proprietary Brain Health AI Platform leveraging Generative AI for mental health and neurodegenerative disorders.

 Latest Interview Insights : AiThority Interview with Ritu Bhargava, Chief Product Officer at SAP CX

 [To share your insights with us, please write to sghosh@martechseries.com]